Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“9 months for docetaxel administered in a different setting but using the same schedule in patients without prior abiraterone in the phase III TAX327 trial [2,33].”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“Based on current phase III data demonstrating good tolerability and an OS benefit for sipuleucel-T [9], the panel agreed it is a reasonable option for patients with asymptomatic or minimally symptomatic mCRPC.”
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“denosumab) or even increase overall survival (OS) (RaCl2 — radium 223 dichloride [Ra223]) [5–13].”
Self-citationAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · cited 1×
“This should be taken into consideration given the OS advantage associated with abiraterone, enzalutamide and cabazitaxel in patients with docetaxel-pretreated mCRPC [6,8,10].”
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationNoonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343 · cited 1×
“Small retrospective studies evaluating patients with progressive CRPC following docetaxel and enzalutamide demonstrated that subsequent abiraterone produced few responses of brief duration [25,26].”
Cited by
Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1584 · Cited by 765
Self-citationExosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., Wang, D., See, W., Costello, B. A., Quevedo, F., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.035 · Cited by 681
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Self-citationOudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357
Self-citation225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 354
Padhani, A. R., Lecouvet, F. E., Tunariu, N., Koh, D.-M., De Keyzer, F., Collins, D. J., Sala, E., Schlemmer, H. P., Petralia, G., Vargas, H. A., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.05.033 · Cited by 333
Self-citationSaad, F., Carles, J., Gillessen, S., Heidenreich, A., Heinrich, D., Gratt, J., Lévy, J., Miller, K., Nilsson, S., Petrenciuc, O., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30173-5 · Cited by 294
Self-citationEndzeliņš, E., Berger, A., Melne, V., Bajo-Santos, C., Soboļevska, K., Ābols, A., Rodriguez, M., Šantare, D., Rudņickiha, A., Lietuvietis, V., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3737-z · Cited by 266
Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.032 · Cited by 185
Self-citationLavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.09.022 · Cited by 63
“Until recently, androgen deprivation therapy (ADT) alone was the standard of care for men with metastatic castration-naive prostate cancer (mCNPC), with anticancer activity initially being reported in the large majority of patients after its initiation [2,3].”
BackgroundSelf-citation
Metadata
- Authors
- Fitzpatrick, J. M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C. N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S. P., Fosså, S., Gillessen, S., Kellokumpu-Lehtinen, P.-L., Lecouvet, F. E., Oudard, S., de Reijke, T. M., Robson, C. N., De Santis, M., Seruga, B., & de Wit, R.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 50
- Issue
- 9
- Pages
- 1617-1627
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2150418305
- Cited by
- 145
- References
- 7
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.